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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To summarise the effects of repellents on preventing new cases of Plasmodium falciparum andPlasmodium vivax malaria.
Specifically, to summarise and evaluate the effect of:
1. Insecticide treated clothing (ITC);
2. Topical repellents; and
3. Spatial repellents.
B A C K G R O U N D
Description of the condition
Malaria is caused by protozoan parasites of the genus Plasmodium.
The most severe form of the disease is caused by P. falciparum.
Other Plasmodium species known to cause milder cases of malaria
includeP. vivax, P. ovale and P. malariae. The parasites are transmit-
ted to people through the bite of an infected Anopheles mosquito.
Malaria is wide spread in tropical and subtropical regions and is
considered endemic in 104 countries worldwide (WHO 2013).
Symptoms of malaria include fever, chills, headache, and vomit-
ing, and usually appear between 10 to 15 days after the bite of an
infectedmosquito. If left untreated, the personmay develop severe
complications and malaria can quickly become life-threatening
by disrupting the blood supply to vital organs. Diagnosis is done
through identification of the Plasmodium parasite in the patient’s
bloodstream, usually by microscopic examination of a blood slide
or malaria rapid diagnostic tests (mRDTs).
In the past decade, great advances have been made in the fight
against malaria. From 2000 to 2012 global incidence of malaria
reduced by 30% and related mortality by 50% (WHO 2013).
This is due to massive scale-up of the vector control interventions
using long lasting insecticide-treated bed nets (LLINs) and indoor
residual spraying (IRS), as well as introduction of mRDTs for bet-
ter malaria diagnosis and use of highly effective artemisinin-based
1Mosquito repellents for malaria prevention (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
combination therapies (ACTs). Despite these developments, an
estimated 3.3 billion people living in 104 countries are still at risk
of contracting malaria and, as a result, 1300 children under 5 years
old die every day inmalaria endemic regions (WHO 2013).While
the vector control component of most national malaria control
programmes concentrates on distribution of LLINs and IRS, there
is substantial malaria transmission within and outside Africa at
times when people are outdoors (Durnez 2013). Recent estimates
are that 16% of global malaria burden and 8% of malaria mor-
tality occurs outside Africa (WHO 2013) where vectors are pri-
marily early evening feeders (Sinka 2010; Sinka 2011). In order
to achieve sustained malaria control and move towards malaria
elimination, new tools will be required to interrupt transmission
in environments where existing tools are not completely effective
(malERA 2011). Residual malaria transmission is maintained by
the presence of asymptomatic carriers, the significant number of
non compliant LLIN users, early evening outdoor feedingAnophe-
les mosquitoes and the spread of drug and insecticide resistance
(White 2014). As well as preventing early evening bites, mosquito
repellentsmay be suitable for people who have a high occupational
risk of contracting malaria, such as: those working at night par-
ticularly in mining; soldiers; people in close contact with forest
ecosystems; and migrants (Onyango 2014). It is well known that
these high-risk individuals “re-seed” malaria in areas where vector
control activities are carried out (Tatem 2010). With the impetus
for malaria eradication of the past decade and the realization that
the existing control tools cannot solely achieve this, mosquito re-
pellents are increasingly being considered as supplementary tools
in some malaria endemic settings (Sturrock 2013).
Description of the intervention
Personal protection has been used for centuries to prevent
mosquito bites (Herodotus 1996). Historically, people burned re-
pellent plants and applied essential oils directly onto their skin or
clothing. In recent times industry has developed more effective
products that have largely replaced traditional methods, including
mosquito coils, long-lasting formulated repellent lotions and in-
secticide treatments for clothing.Mosquito repellents are currently
recommended by the World Health Organization (WHO) as the
first-line malaria prevention tool for travellers (WHO 2012) and
are commonly used by expatriates in tropical developing countries.
There are three main interventions that result in mosquito bite
prevention:
1. Wearing insecticide-treated clothing (ITC);
2. Applying topical repellents directly onto the skin; and
3. Using spatial repellents.
The mode of action of these three intervention types on the
mosquito is not the same, however they all result in preventing
mosquito bites and so potentially reduce transmission of Plasmod-
ium parasites from infected mosquitoes to humans.
ITC
ITC is widely used by military personnel to protect against vector
borne diseases and biting nuisance (Kitchen 2009). The synthetic
pyrethroid permethrin (2 g/m2) is used most commonly for treat-
ment of clothing. Permethrin is approved by the WHO for this
purpose because of its low dermal absorption, low mammalian
toxicity, no odour and minimal irritation (WHOPES 2006). The
mode of action of ITC is through contact irritancy, whereby
mosquitoes make oriented movement away from the person after
physical contact with the treated clothing surface, and it also af-
fects mosquito feeding response. Both of these modes of actions
result in a reduction in mosquito bites to the ITC user.
Topical repellents
Topical repellents may contain a wide range of active ingredients
and are available in various formulations, lotions, gels, roll-ons,
and onwipes. Approved active ingredients formosquito-borne dis-
ease prevention are DEET (chemical name: N,N-diethyl-m-tolu-
amide or N,N-diethyl-3-methyl-benzamide), icaridin (KBR 3023
[Bayrepel] and picaridin inside the United States; chemical name:
2-2-hydroxyethyl-1-piperidinecarboxylic acid 1-methylpropyl es-
ter), PMD (para-methane-3,8-diol), and IR3535 (chemical name:
3-[N-butyl-N-acetyl]-aminopropionic acid, ethyl ester) (WHO
2012; CDC 2014). The Environmental Protection Agency (EPA)
estimated that approximately 200 million people are exposed an-
nually to DEET worldwide (WHOPES 1998). Each repellent
molecule has a different mode of action on mosquito olfactory
receptors, but all prevent mosquito bloodfeeding and result in re-
duced man-biting rates.
Spatial repellents
Spatial repellents disperse active ingredients into the surrounding
air that interfere with the mosquito’s ability to find a host, thus
preventing mosquitoes from taking a blood meal. They may in-
terfere with host detection or through excito-repellency, causing
insects to fly in an undirected manner until they eventually move
away from the source of repellent vapour. Spatial repellents create
a protective area within a given radius and can be used to protect
more than one person at the same time. Dispersal of the active
ingredient can be done in two ways:
1. Through heat ( for example, mosquito coil and electric
emanators); or
2. Through evaporation (for example, passive emanators made
of paper or agarose gel).
The most popular format is the mosquito coil and an estimated
45to 50 billion mosquito coils are used annually by approximately
two billion people worldwide, mainly in Southeast Asia (Zhang
2010). Mosquito coils are made from a mixture of inert ingredi-
ents, such as sawdust or coconut husks, and pigment that burns
at a low temperature dispersing the active ingredient, usually a
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volatile pyrethroid with a quick knock-down action (for example,
pyrethrin, D-allethrin, transfluthrin, or metofluthrin). The smoke
produced by the burning of mosquito coils can cause indoor air
pollution.
Electric emanators consist of an electrical heating agent that va-
porizes insecticide that has been impregnated into a pad or wick.
These produce no smoke but require a source of electricity, which
is not available in a large proportion of the homes in malariaen-
demic countries.
Passive emanators do not require a source of heat or combustion.
They have a large surface area which allows the passive dispersal of
the volatile active ingredient into the air by evaporation without
the need for an external source of energy. The chosen active in-
gredients are predominantly less polar compounds that are easily
volatilised. Examples include metofluthrin and transfluthrin.
How the intervention might work
During the first Global Malaria Eradication Campaign the con-
cept of vectorial capacity was developed and validated to mathe-
matically evaluate the impact of mosquito control interventions
on malaria transmission using several measurable field parameters
(Garrett-Jones 1964). Vectorial capacity is defined as: “the daily
rate at which future inoculations of a parasite arise from a cur-
rently infective case, provided that all female vectors biting that
case become infected” (Garrett-Jones 1964). The original valida-
tion demonstrated that by reducingman-vector contact (mosquito
bites) by 50% there was a consequent 75% reduction in vectorial
capacity. Man-vector contact can be reduced by using repellents.
Mosquitoes will be repelled or disabled from feeding on a person
while being exposed to the repellent. These personal protective
measures can be used at any time or location, and so are suit-
able for controlling mosquitoes biting outdoors and during early
evening hours before people retire to bed. Repellents also protect
individuals from all mosquito-borne diseases because they stop
the mosquito from biting and therefore prevent transmission of
pathogens through the mosquito bite.
Why it is important to do this review
The wide distribution of LLINs in malaria-endemic countries
has resulted in a considerable reduction of malaria incidence and
prevalence throughout affected areas (WHO 2013). However,
LLINs only protect people while they are under them. It is esti-
mated that in South America and Southeast Asia 80% of malaria
transmission occurs before sleeping hours. Even in Africa, where
Anopheles mosquitoes vectors are traditionally late feeders, up to
20% of malaria transmission is taking place during early evening
and early morning hours (Onyango 2014). During this time the
only available means of protection are repellents and ITC. These
interventions may reduce existent residual malaria transmission,
by protecting people outside of LLINs. This Cochrane Review
aims tomeasure the effectiveness of these interventions in reducing
the incidence of malaria alone and when combined with LLINs
to facilitate decision makers considering including repellents in
national malaria control programmes. In addition, we believe that
this review may be helpful to reach three of the United Nations
Millennium Development Goals (MDGs):
• MDG 04: To reduce child mortality rates. Reducing the
number of mosquito bites a child receives has been shown to
lower the morbidity from malaria (Snow 1998). Repellents may
also reduce other vector-borne diseases as the most widely used
repellents are broad spectrum and prevent bites from a range of
disease vectors.
• MDG 05: To improve maternal health. Pregnant women
are more attractive to mosquitoes and therefore at a higher risk of
infection than when the same women are not pregnant. In
addition, pregnant women are particularly susceptible to
complications of malaria. Modern repellents are safe to use
among pregnant women and therefore have the potential to
confer protection to a high-risk group.
• MDG 06: To combat HIV/AIDS, malaria, and other
diseases.
O B J E C T I V E S
To summarise the effects of repellents on preventing new cases of
Plasmodium falciparum andPlasmodium vivax malaria.
Specifically, to summarise and evaluate the effect of:
1. Insecticide treated clothing (ITC);
2. Topical repellents; and
3. Spatial repellents.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs), randomized by cluster or
individual.
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Types of participants
Adults and children living in malaria-endemic areas.
In areas endemic for P. vivax, we will only include trials in which
participants have been screened at the trial start and Plasmodium
parasites have been cleared. Thus, only new cases of malaria that
are preventable by the intervention, and not recrudescence of a
dormant infection, will be measured.
Types of interventions
We will include trials with or without LLINs in both trial arms.
Intervention
• ITC impregnated with permethrin; or
• Topical repellents including DEET, icaridin, IR3535 and
PMD; or
• Spatial repellents including transfluthrin coils, metofluthrin
coils, D-allethrin coils, pyrethrin coils, metofluthrin emanators
and transfluthrin emanators.
Control
Individuals given a placebo or no treatment.
Types of outcome measures
Primary outcomes
• Clinical malaria confirmed through blood smears or rapid
diagnostic tests (P. falciparum or P. vivax).
• Participants with Plasmodium parasitaemia confirmed
through thick or thin blood smears, mRDTs, or polymerase
chain reaction (PCR) (P. falciparum or P. vivax).
Secondary outcomes
• Anaemia (haemoglobin < 8 g/dL);
• Time to first infection (days);
• All-cause fever;
• Adherence to regular usage of the intervention measured
through spot-checking per period of time; and
• Reduction in mosquitoes attempting to feed on humans.
Recorded adverse events
• Skin irritation;
• Irritation of upper airways;
• Nausea; and
• Headaches.
Search methods for identification of studies
Wewill attempt to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
We will search the following databases using the search terms
and strategy described in Appendix 1: Cochrane Infectious Dis-
eases Group Specialized Register; Central Register of Controlled
Trials (CENTRAL), published in The Cochrane Library; MED-
LINE; EMBASE; United States Armed Forces Pesticide Man-
agement Board (US AFPMB); CAB Abstracts; and LILACS up
to present. We will also search the WHO International Clinical
Trials Registry Platform and the metaRegister of Controlled Tri-
als (mRCT) using ’mosquito*’, ’malaria’, DEET, PMD, IR3535,
Icaridin, Metofluthrin, Transfluthrin, and repellent,*’ as search
terms.
Searching other resources
Conference proceedings
Wewill search the following conference proceedings of the relevant
abstracts:
• MIM conference abstract booklets (2008 to present);
• Annual ASTMH conference (2008 to present);
• Entomological Society of America (2008 to present); and
• Society of Vector Ecology of America (2008 to present).
Organisations and pharmaceutical companies
We will contact organizations including the WHO, and Centers
for Disease Control and Prevention (CDC), United States De-
partment of Agriculture(USDA), United States Agency for In-
ternational Development (USAID), US AFPMB, Deployed War
Fighter Protection Program (DWFP) and chemical companies in-
cluding Bayer, Sumitomo, Vestergaard-Frandsen, BASF, SC John-
son, Insect Shield, Mosiguard, Sara Lee, Syngenta, and other local
companies for ongoing and unpublished trials.
Reference lists
Wewill also check the reference lists of all included trials for further
relevant studies.
Data collection and analysis
Selection of studies
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Three review authors (MM, MK, and SM) will independently
assess the titles and abstracts of trials identified by the searches.
The same three review authors will assess full text copies of poten-
tially relevant trials for inclusion using an eligibility form based
on inclusion criteria. We will compare included trials, and resolve
any disagreements by discussion and consensus, with arbitration
by the fourth review author (CL) if necessary. We will ensure that
multiple publications of the same trial are included once. We will
list excluded studies, together with their reasons for exclusion, in
table format.
Data extraction and management
Three review authors (MM, MV, and SM) will independently ex-
tract information from the trials using pre-piloted, electronic data
extraction forms. In case of differences in extracted data, the three
review authors will discuss these differences to reach consensus. If
unresolved, further discussion will involve the fourth author (CL).
In case of missing data, we will contact the original trial author(s)
for clarification. We will include all RCTs published in Chinese
journals after contacting the trial authors and determining the ad-
equacy of randomization (Wu 2009).
We will extract data on the following:
1. Trial design: Type of trial; method of participant selection;
unit of randomization (for RCTs); adjustment for clustering (for
cluster RCTs (cRCTs)); sample size; method of blinding of
participants and personnel; diagnostic method; primary vector;
vector biting time; malaria endemicity; Plasmodium species;
2. Participants: Trial settings and population characteristics;
recruitment rates; withdrawal and loss to follow-up;
3. Intervention: Description of intervention; co-interventions;
description of controls; time of follow-up; passive or active case
detection; compliance; and
4. Outcomes: Defininition of outcome; number of events;
number of participants; power; unit of analysis; incomplete
outcomes/missing data.
For dichotomous outcomes, we will extract the number of patients
experiencing each outcome and the number of patients in each
treatment group. For count data outcomes, we will extract the
number of outcomes in the treatment and control groups, and
the total person time at risk in each group or the rate ratio, and a
measure of variance (for example, standard error). For numerical
outcomes, that is time to first infection (days), we will extract the
mean and a measure of variance (standard deviation).
RCTs randomized by the individual
We will extract information on the number of participants ran-
domized to each treatment arm; and the number of events in each
of the treatment arms (present or absent) in person/weeks.
cRCTs
For cRCTs we will record the number of clusters randomized;
number of clusters analysed; measure of effect (such as risk ratio,
odds ratio, or mean difference) with confidence intervals (CI) or
standard deviations; number of participants; and the intra-cluster
correlation coefficient (ICC) value.
Assessment of risk of bias in included studies
Three review authors (MM, MK, and SM) will independently as-
sess risk of bias for each included trial using the the Cochrane Col-
laboration’s ’Risk of bias’ tool (Higgins 2011). Any discrepancies
will be resolved through discussion or by consulting the fourth
review author (CL). We will classify judgements of risk of bias
as either low, high or unclear risk of bias, using summary graphs
(’Risk of bias’ summary and ’Risk of bias’ graph) to display results.
We will assess each of the following components for each included
RCT randomized by the individual and by cluster:
Sequence generation
We will describe the methods used to generate the allocation se-
quence in sufficient detail to allow an assessment of whether it
produced comparable groups. We will regard a trial as having a
low risk of selection bias if the sequence generation was truly ran-
dom (for example, computer-generated table of random numbers,
tossing a coin); a high risk of bias if sequence generation was non-
random (for example, alternate randomization, randomization by
birth date); and unclear risk of bias if the randomization process
was not clearly described.
Balance
Regardingbalance, wewill assess if both arms of the trial are equally
balanced at baseline using criteria including age, gender, malaria
indicators, socioeconomic status, housing, use of other interven-
tions, knowledge about malaria transmission, and occupation.
Allocation concealment
We will describe the method used to conceal allocation to treat-
ment groups before assignment. We will regard trials as having a
low risk of selection bias if allocation was truly concealed (for ex-
ample, central allocation of participants, use of sequentially num-
bered, opaque, sealed envelopes, lottery system); a high risk of bias
if the allocation process was not concealed (for example, open ran-
domization, unsealed or non-opaque envelopes); and an unclear
risk of bias if the process of concealing allocation was not described
sufficiently to make a judgement.
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Blinding of participants and personnel
We will describe whether blinding was present, who was blinded,
and the methods used to blind trial participants and personnel.
We will regard a trial as having a low risk of performance bias if
blinding was present, or if the absence of blinding was unlikely to
affect the outcomes; high risk of bias if blinding was absent and
likely to affect the results; and unclear risk of bias if blinding was
not clearly described.
Blinding of outcome assessors
Regarding blinding of outcome assessors, we will describe whether
blinding of outcome assessors was present, and how they were
blinded. We will regard a trial as having a low risk of detection
bias if they were blinded to knowledge about which intervention
the participants received; high risk of bias if blinding was absent;
and unclear risk if blinding was not clearly described.
Incomplete outcome data
We will describe the percentage and proportion loss to follow-up;
reasons for attrition; and whether attrition was balanced across
groups or related to outcomes. We will regard trials as having a low
risk of attrition bias if there was no missing data or if missing data
was balanced across groups or clusters; high risk of bias if there was
missing data or if missing data was more prevalent in one of the
groups; and unclear risk of bias if it is unclear whether outcome
data is missing.
Selective outcome reporting
We will record any discrepancies between the pre-specified out-
comes in the methods section and the outcomes reported, and will
attempt to identify outcomes that were measured but not reported
on. We will regard a trial as having low risk of reporting bias if it
is evident that all pre-specified outcomes have been reported on;
high risk of bias if it is evident that not all pre-specified outcomes
were reported on; and unclear risk of bias if it is unclear whether
all outcomes were reported on.
Incorrect analysis
We will describe whether the analysis was appropriate, an analysis
plan was followed, and if it was adjusted for clustering.
Other bias
Wewill describe any important feature of included trials that could
have affected the result.
In addition to the above, we will assess the following for each
included cRCT:
Recruitment bias
Regarding recruitment bias, we will describe whether participants
were recruited before or after randomization of clusters. We will
regard trials as having low risk of recruitment bias if participants
were recruited before randomization of clusters; high risk of bias
if they were recruited after randomization; and unclear risk of bias
if information about the timing of recruitment is unclear.
Loss of clusters
We will describe the number of clusters lost, as well as the reasons
for attrition.
Compatibility with RCTs randomized by individuals
Wewill notewhether the intervention effectsmay be systematically
different from individually RCTs, that is, whether it was likely that
the effect size was over- or underestimated.
Measures of treatment effect
We will compare intervention and control data using risk ratios.
All results will be presented with their associated 95% CIs.
Unit of analysis issues
We will combine results from cRCTs with individually RCTs if
they have adjusted for clustering in their analysis and present re-
sults using forest plots. If there was no adjustment for clustering
in RCTs, we will attempt to adjust data before combining it with
data from individually RCTs. We will attempt to adjust the data
by multiplying standard errors by the square root of the design
effect (Higgins 2011). If the trial does not report the ICC value,
then we will estimate the ICC from a similar trial if possible, or
by searching external sources for example ICCs. Alternatively, we
will not include cRCTs that have not adjusted for clustering in the
meta-analysis but will present results in a separate table.
Dealing with missing data
In case of missing data, we will apply available case analysis, only
including data on the known results. The denominator will be
the total number of participants who had data recorded for the
specific outcome. For outcomes with no missing data, we plan to
carry out analyses on an intention-to-treat basis. We will include
all participants randomized to each group in the analyses and will
analyse participants in the group to which they were randomized
to.
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Assessment of heterogeneity
We will inspect forest plots for overlapping CIs and will assess
statistical heterogeneity in eachmeta-analysis using the I² andChi²
statistics. We will regard heterogeneity as moderate if I² values
are between 30 to 60%; substantial if they are between 59 to
90%; and considerable if they are between 75 to 100%. We will
regard a Chi² test statistic with a P value ≤ 0.10 indicative of
statistically significant heterogeneity. Clinical and methodological
heterogeneity will be explored through consideration of the trial
populations, methods and interventions, and by visualisation of
trial results.
Assessment of reporting biases
If there are 10 or more trials included in each meta-analysis, we
will investigate reporting biases (such as publication bias) using
funnel plots. We will assess funnel plot asymmetry visually, and
use formal tests (Harbord 2006) for funnel plot asymmetry. If we
detect asymmetry in any of these tests or by a visual assessment,
we will explore reasons for asymmetry.
Data synthesis
We will group trials and analyse by intervention:
1. Topical repellents;
2. Spatial repellents;
3. ITC.
Within each group, we will stratify by whether LLINs were in-
cluded in both intervention and control groups.
We will analyse data using Review Manager 2014 software. We
will use fixed-effect meta-analysis to combine data if heterogeneity
is absent. If considerable heterogeneity is present, we will com-
bine data using random-effectsmeta-analysis and report an average
treatment effect. We will decide whether to use fixed or random-
effects based on the consideration of clinical and methodological
heterogeneity between trials, as described previously.
Quality of evidence
We will rate the quality of evidence using the GRADE approach
(Guyatt 2011). Each important outcome will be rated as described
by Balshem 2011:
1. High: We are very confident that the true effect lies close to
that of the estimate of the effect;
2. Moderate: We are moderately confident in the effect
estimate. The true effect is likely to be close to the estimate of
the effect;
3. Low: Our confidence in the effect estimate is limited. The
true effect may be substantially different from the estimate of the
effect; or
4. Very low: We have very little confidence in the effect
estimate. The true effect is likely to be substantially different
from the estimate of effect.
RCTs start as high quality evidence but can be downgraded if
there are valid reasons within the following five categories: risk
of bias, imprecision, inconsistency, indirectness, and publication
bias. Studies can also be upgraded if there is a large effect; a dose-
response effect; and if all plausible residual confounding would
reduce a demonstrated effect or would suggest a spurious effect if
no effect was observed (Balshem 2011). We will summarize our
findings in a ’Summary of findings’ table.
Subgroup analysis and investigation of heterogeneity
We will explore reasons for substantial heterogeneity using sub-
group analysis. We plan to perform the following subgroup anal-
yses:
1. Malaria prevalence in children under five years old:
i) Holoendemic (> 20%);
ii) Mesoendemic (10 to 20%);
iii) Hypoendemic (< 10%).
2. Measure of compliance with intervention:
i) High (> 80%);
ii) Moderate (50 to 80%);
iii) Low (< 50%).
3. Malaria diagnostic method:
i) mRDTs;
ii) Blood smear (thick or thin);
iii) PCR.
We will assess differences between subgroups using the Chi2 test,
with a P value≤ 0.05 indicating statistically significant differences
between subgroups.
Sensitivity analysis
Wewill perform sensitivity analysis on the primary outcome to see
the effect of exclusion of trials at high risk of bias (for allocation
concealment and incomplete outcome data) on overall results. The
same analysis will be done to investigate whether the exclusion of
cRCTs affects results, as well as whether being placebo-controlled;
and to see what effect missing data has on results. If the ICC value
is estimated, we will carry out sensitivity analyses to investigate
the impact of varying the ICC on results from the meta-analysis.
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A P P E N D I C E S
Appendix 1. Search strategy
Search set Search terms a
1 Malaria* ti, ab
2 “Insect Vectors”[Mesh] OR vector* ti, ab OR mosquito* ti, ab
3 1 or 2
4 “Mosquito Control”[Mesh]
5 “Anopheles”[Mesh]
6 3 or 4 or 5
7 Repellen* ti, ab
8 “Insecticide treated clothing” OR ITC ti,ab
9 Spray OR sprays OR lotion* OR gel OR gels OR roll-on* OR wipe* ti, ab
10 Coil* ti, ab
11 “passive emanator*” ti, ab
12 “electric emanator*” ti, ab
13 “vaporizer mat*” ti, ab
14 “personal protection*” ti, ab
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(Continued)
15 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16 6 and 15
aSearch terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Lefebvre
2011).
This is the preliminary search strategy we will use for MEDLINE (Pubmed). We will adapt it to search the other electronic databases
listed in the Methods section. All search strategies will be reported in full in the final version of the review.
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